SCM
UTHR icon

Superstring Capital Management’s United Therapeutics UTHR Stock Holding History

Superstring Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.08M Sell
5,186
-4,265
-45% -$2.12M 2.2% 18
2025
Q4 		$4.61M Buy
+9,451
New +$4.4M 2.47% 15
2025
Q3 		– Sell
-4,874
Closed -$1.4M – 48
2025
Q2 		$1.4M Buy
+4,874
New +$1.46M 1.66% 21

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Superstring Capital Management's UTHR Position: Q1 2026 in Review

Superstring Capital Management reduced its United Therapeutics (UTHR) stake by 45% in Q1 2026, selling an estimated $2.12M and leaving 5,186 shares worth $3.08M. The position accounts for 2.2% of the portfolio, ranked #18.

Superstring Capital Management first reported a position in UTHR in Q2 2025 and has held it in 3 quarters since. The position peaked at $4.61M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Superstring Capital Management held 5,186 shares of United Therapeutics worth $3.08M as of Q1 2026.
  • Superstring Capital Management sold 4,265 United Therapeutics shares in Q1 2026, an estimated $2.12M.
  • United Therapeutics made up 2.2% of Superstring Capital Management's portfolio in Q1 2026, its #18 holding.
  • Superstring Capital Management first reported a position in United Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Superstring Capital Management's United Therapeutics position peaked at $4.61M in Q4 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.